Antimycobacterial activity of bacteriocins and their complexes with liposomes

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 5, 2007, Pages 919-925

  Sosunov, Vasily ^a   Mischenko, Vladimir ^a   Eruslanov, Boris ^b   Svetoch, Edward ^b   Shakina, Yulia ^c   Stern, Norman ^d   Majorov, Konstantin ^a   Sorokoumova, Galina ^c   Selishcheva, Alla ^c,e   Apt, Alexander ^a  

^a CENTRAL TUBERCULOSIS RESEARCH INSTITUTE   (Russian Federation)

^b STATE RESEARCH CENTER FOR APPLIED MICROBIOLOGY AND BIOTECHNOLOGY   (Russian Federation)

^c MIREA RUSSIAN TECHNOLOGICAL UNIVERSITY   (Russian Federation)

^d RUSSELL RESEARCH CENTER   (United States)

^e MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Mouse model; Mycobacterium tuberculosis; Tuberculosis chemotherapy

Indexed keywords

AMINO ACID; BACTERIOCIN; CARDIOLIPIN; LIPOSOME; PHOSPHATIDYLCHOLINE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG TOLERABILITY; EUKARYOTIC CELL; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; INBRED STRAIN; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN ISOLATION; PROTEIN PURIFICATION; SUPERNATANT; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; BACTERIOCINS; LIPOSOMES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN;

EID: 34447569200     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm053     Document Type: Article

References (24)

1. WHO Report. Global Tuberculosis Control - Surveillance, Planning, Financing. Geneva, Switzerland: WHO, 2005.
2. Dye C, Watt CJ, Bleed D. Low access to a highly effective therapy: A challenge for international tuberculosis control. Bull World Health Organ 2002; 80: 437-44.
3. Iseman MD. Tuberculosis therapy: Past, present and future. Eur Respir J 2002; 20 Suppl 36: 87s-94s.
4. Fine P. BCG: The challenge continues. Scand J Infect Dis 2001; 33: 243-5.
5. O'Brien RJ, Spigelman M. New drugs for tuberculosis: Current status and future prospects. Clin Chest Mad 2005; 26: 327-40.
6. Andries K, Verhasselt P, Guillemont et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
7. Lee RE, Protopopova M, Crooks E et al. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinicall candidates. J Comb Chem 2003; 5 172-87.
8. Protopopova M, Hanrahan C, Nikonenko B et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005; 56: 968-74.
9. Chatterjee C, Paul M, Xie L et al. Biosynthesis and mode of action of lantibiotics. Chem Rev 2005; 105: 633-84.
10. Guinane CM, Cotter PD, Hill C et al. Microbial solutions to microbial problems; lactococcal bacteriocins for the control of undesirable biota in food. J Appl Microbiol 2005; 98: 1316-25.
11. Hechard Y, Sahl HG. Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria. Biochimie 2002; 84 545-57.
12. Drider D, Fimland G, Hechard Y et al. The continuing story of class lla bacteriocins. Microbiol Mol Biol Rev 2006; 701: 564-82.
13. Zhang Y, Vilcheze C, Jacobs WR Jr. Mechanisms of drug resistance in Mycobacterium tuberculosis. In: Cole ST, Eisenach KD, McMurray DN et al., eds. Tuberculosis and the Tubercle Bacillus. Washington, DC: ASM Press, 2005; 115-40.
14. Svetoch E, Stern NJ, Eruslanov BV et al. Isolation of Bacillus circulans and Paenibacillus polymyxa strains inhibitory to Campylobacter jejuni and characterization of associated bacteriocins. J Food Protect 2005; 68: 107-13.
15. Jorgensen JH, Redding JS, Maher LA et al. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol 1987; 25: 2105-13.
16. Bhunia AK, Johnson MC, Ray B. Purification, characterization and antimicrobial spectrum of a bacteriocin produced by Pediococcus acidilactici. J Appl Bacteriol 1988; 65: 261-8.
17. Rodriguer-Vico F, Martinez-Caynela M, Garcia-Perigrin E et al. A procedure for eliminating interferences in the Lowry method of protein determination. Anal Biochem 1989; 183: 275-8.
18. Svetashev VI, Vaskovsky VE. Phospholipid spray reagents. J Chromatogr 1972; 65: 451-3.
19. Majorov KB, Lyadova IV, Kondratieva TK et al. Different innate ability of I/St and A/Sn mice to combat virulent Mycobacterium tuberculosis: Phenotypes expressed in lung and extrapulmonary macrophages. Infect Immun 2003; 71: 697-707.
20. Apt AS, Nickonenko BV, Avdeenko VG et al. Distinct H-2 complex control of mortality and immune responses to tuberculosis infection in virgin and BCG-vaccinated mice. Clin Exp Immunol 1993; 94: 322-32.
21. Russel DG. Mycobacterium tuberculosis: Here today, and here tomorrow. Nat Rev Mol Cell Biol 2001; 2: 569-77.
22. Muñoz-Elias E, McKinney JD. Carbon metabolism of intracellular bacteria. Clin Mirobiol 2006; 8: 10-22.
23. Nikonenko BV, Samala R, Einck L et al. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 4550-5.
24. D'Costa VM, McGrann KM, Hughes DW et al. Sampling the antibiotic resistome. Science 2006; 311: 374-7.